Published in final edited form as:

Fertil Steril. 2011 June 30; 95(8): 2718–2721. doi:10.1016/j.fertnstert.2011.05.051.

Serum antimüllerian hormone in healthy premenopausal women

Christiana M. Shaw, M.D., M.S.^a, Frank Z. Stanczyk, Ph.D.^b, Brian L. Eggleston, Ph.D.^c, L.L. Kahle, B.A.^d, Cynthia S. Spittle, Ph.D.^e, Andrew K. Godwin, Ph.D.^f, Louise A. Brinton, Ph.D.^g, and Joanne F. Dorgan, Ph.D.^c

^aDepartment of Surgery, University of Florida, Gainesville, Florida ^bUniversity of Southern California Keck School of Medicine and Women's and Children's Hospital, Los Angeles, California ^cFox Chase Cancer Center, Philadelphia, Pennsylvania ^dInformation Management Services, Rockville, Maryland ^eMolecular MD Corporation, Portland, Oregon ^fDepartment of Pathology and Laboratory Medicine, University of Kansas, Kansas City, Kansas ^gNational Cancer Institute, Rockville, Maryland

Abstract

Antimüllerian hormone (AMH) is extensively studied in ovarian aging and pathology; however, little is known about correlates in healthy premenopausal women. We found that AMH levels are strongly inversely associated with age and differed significantly between oral contraceptive pill users and nonusers, whereas no significant associations were seen between AMH and other clinical, behavioral, and anthropometric characteristics and laboratory variables, making it an attractive hormone for clinical applications.

Keywords

Müllerian-inhibiting substance (MIS); antimüllerian hormone (AMH); ovary; premenopausal; healthy

Antimüllerian hormone (AMH) is growth factor within the transforming growth factor- β family. In women, AMH is expressed by ovarian granulosa cells and controls the recruitment and growth of primary follicles. Levels correlate with the number of antral follicles, which predictably decline with age and disappear at menopause (1, 2). Levels of AMH do not fluctuate significantly across the menstrual cycle, and levels are independent of FSH, LH, and E₂ levels (1, 3, 4). These characteristics make AMH a unique ovarian hormone and an attractive target for study.

The role of AMH in various pathologic conditions, including polycystic ovary syndrome (PCOS) and ovarian granulosa cell tumors, as well as in IVF, has been well defined. Although AMH is extensively studied in these circumstances, little is known about its correlates in healthy women. The purpose of our study was to define associations in healthy premenopausal women between AMH concentration and anthropometric, behavioral, temporal, and seasonal characteristics, as well as serum concentrations of steroid sex hormones.

©2011 by American Society for Reproductive Medicine.

Reprint requests: Christiana M. Shaw, M.D., M.S., University of Florida, Department of Surgery, 1600 SW Archer Road, P.O. Box 100109, Gainesville, FL 32610 (christiana.shaw@surgery.ufl.edu).

C.M.S. has nothing to disclose. F.Z.S. has nothing to disclose. B.L.E. has nothing to disclose. L.L.K. has nothing to disclose. C.S.S. has nothing to disclose. A.K.G. has nothing to disclose. L.A.B. has nothing to disclose. J.F.D. has nothing to disclose.

Subjects were selected from the control population in a prospective case-control study on the association of AMH and breast cancer risk (5) nested in the Columbia, Missouri Serum Bank. Participants were volunteers in the National Cancer Institute's Biological Markers Project who were identified primarily through the Breast Cancer Detection Demonstration Project at the University of Missouri Hospital and Ellis Fischel Cancer Center in Columbia, Missouri. All gave informed consent and donated blood to the bank between 1977 and 1987. Initial follow-up continued until 1989. The National Cancer Institute conducted an extended follow-up in 1999–2004. Women were eligible to be controls in the breast cancer case-control study if they were premenopausal at blood collection and had never been diagnosed with cancer other than nonmelanoma skin cancer ($n = 258$). Because the frequency of immeasurable AMH values increases dramatically as women approach menopause, women close to menopause provide limited information about clinical correlates of AMH levels. Thus, we limited our evaluation to the 135 women who were premenopausal and younger than 45 years. For 80% of women, data were available on start of last menses, and all of these women were within 33 days of the start of their last menstrual cycle at the time of blood collection. Because of our age restriction, we presumed that the remaining 20% without data on last menses also were premenopausal.

Demographic, anthropometric, and behavioral data were collected, including age, height, weight, menstrual and reproductive histories, smoking, hormone use, and family history of breast cancer. Approximately 30 mL of blood were collected from each woman and processed and stored using standard procedures.

At the initiation of our investigation, AMH was quantified by ELISA using a commercially available kit (Beckman-Coulter Diagnostics Systems Laboratories). The AMH interassay coefficient of variation averaged 8.2%, and its limit of detection (LOD) was 0.43 pmol/L.

The association of AMH with individual characteristics was evaluated using nonparametric statistics because of the extreme skewness of the data. Univariate tests of significance were performed using Wilcoxon rank-sum and Kruskal-Wallis tests. Analyses were age adjusted by including age as a continuous term in regression models. Adjusted medians were estimated using median regression with bootstrap variances. Tests for trend were performed by including quantile rank in models as an ordinal variable. Because AMH levels differed by oral contraceptive pill (OCP) use, analyses were repeated to control for OCP use and age. For evaluation of sex hormone levels, women taking OCPs and women with unknown menstrual cycle day were eliminated from the analysis. Additionally, a restricted cubic spline for cycle day, using the method of Harrell (6), was included in E_2 models to account for the variation of this hormone over the menstrual cycle. For women with AMH levels below the assay LOD, the value was imputed using 0.21 pmol/L, the midpoint between 0 and the assay LOD. Two-sided P values $< .05$ were considered statistically significant. All analyses were performed using Stata 10 (StataCorp).

All women were Caucasian, and their mean ($\pm$ SD) age was 41 ± 2.48 years. Their mean body mass index (BMI) was 25 ± 5.15 kg/m². Sixty percent were normal weight, 24% were overweight, and 16% were obese. Ninety percent of the women were not using OCPs, and 96% were parous at the time of blood collection, with an average of 2.8 ± 1.36 children per woman. Blood collection occurred from 8:00 AM to 4:00 PM, and draws were evenly distributed throughout this time frame.

The median overall AMH level was 3.57 pmol/L (95% confidence interval [CI], 2.14–4.57 pmol/L). Antimüllerian hormone was strongly inversely associated with age (trend $P < .001$), declining from a median of 7.85 pmol/L in the youngest women (95% CI, 5.21–10.00 pmol/L) to 0.50 pmol/L (95% CI, 0.21–1.43 pmol/L) in the oldest (see Table 1). This substantiates

previous findings that AMH concentration declines significantly with increasing age in premenopausal women (7–9). Over the age range of premenopausal women included in these analyses, a near-linear relationship between serum AMH level and age was observed.

After adjusting for age, AMH levels differed significantly between users and nonusers of OCPs ($P=.001$). The median AMH level in users was 3.00 pmol/L (95% CI, 2.07–3.86 pmol/L), compared with 4.57 pmol/L (95% CI, 3.86–5.21 pmol/L) in nonusers. These findings are consistent with a clinical trial in which OCPs lowered AMH levels (10) and one in which AMH concentration was found to increase during the hormone-free interval in OCP users (11). However, in two other small clinical trials, treatment with OCPs did not affect serum AMH levels in healthy women (12, 13) or in patients with PCOS (12). These discrepancies may also be related to the differences in OCP preparations, because those used in the late 1970s when our data were collected were stronger than those used recently (14). Notably, few patients were taking OCPs, therefore this association should be explored in a larger group of women. Additionally, adjustment for OCP use in addition to age did not alter any associations between AMH and other variables.

No significant associations were seen between AMH and anthropometric, menstrual, or reproductive characteristics, including BMI, smoking status, menstrual cycle phase, and temporal or seasonal characteristics of blood collection. Regarding BMI and AMH, conflicting data exist. Three previous studies show that healthy obese women have lower AMH levels compared with their nonobese counterparts (15–17); however, BMI was not associated with serum AMH concentrations in normo-ovulatory women undergoing infertility workups (18). The explanation of the discrepancy between the findings remains unclear. Regarding smoking, one report noted a difference in AMH concentration between smokers and nonsmokers, although this was only significant in late-reproductive and perimenopausal women, of whom 16% had undetectable AMH levels. The correlation was not present among premenopausal women not using OCPs (19). Similar to our findings, other reports agree that AMH concentration does not vary by menstrual phase (3, 20–23). This is in contrast to other ovarian hormones that display considerable cyclic variation. Our evaluation does not support the assertion that differences in findings across studies are due to timing of blood collection (24).

Associations between AMH and serum E_2 , T, or sex hormone-binding globulin (SHBG) levels were not seen (data not shown). Estradiol, T, and their biological fractions generally increased with increasing AMH level, but tests for trend were not statistically significant. Regarding E_2 , this is consistent with most studies (8, 22, 25–28). Antimüllerian hormone concentration was previously reported to be positively associated with T in healthy women (29), but results are not consistent across studies (28). In contrast, SHBG levels decreased with increasing AMH, but the trend was not statistically significant. In analyses that adjusted for menstrual cycle day or phase, AMH concentration was not significantly associated with sex hormones.

Investigators have reported on correlates of serum AMH levels in PCOS, IVF, and cancer patients. However, limited data exist for healthy women, and a major strength of our analysis is that it defines associations between AMH concentrations and characteristics of healthy premenopausal women. Antimüllerian hormone was analyzed in serum using an ELISA that has been shown to be valid and reproducible (3, 30). We also were able to take advantage of newer statistical methods for analyzing skewed data that are included in commercially available statistical software packages. There were also several limitations to our study. Our sample size may not have sufficient power to detect true associations that exist among certain variables. Point estimates for age at menarche, bioavailable E_2 , bioavailable T, and SHBG suggest that there might be trends that would be uncovered if

more samples were available for analysis. Although values of some variables of interest, such as BMI, were reasonably distributed across the expected range, for other variables distributions were limited. Few women were nulliparous, making conclusions regarding AMH and parity tenuous.

Antimüllerian hormone has many characteristics favorable for use in the clinical arena. Its independence of temporal, anthropometric, and behavioral characteristics makes it particularly attractive for clinical applications in women. Although we observed associations between AMH and certain variables in premenopausal women, AMH exerts complex physiologic responses beyond our current understanding. Future areas of study should include both the relationships between AMH in healthy women and those with disease.

Acknowledgments

The authors thank all of the participants of the Columbia, Missouri Serum Bank.

Supported by the US Department of Defense (grant no. BC062367), the National Institutes of Health (grant no. P30CA006927), the US Department of Health and Human Services (grant no. T32CA103652), and by the National Institutes of Health Intramural Research Program.

References

1. Feyereisen E, Mendez Lozano DH, Taieb J, Hesters L, Frydman R, Fanchin R. Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status. *Reprod Biomed Online*. 2006; 12:695–703. [PubMed: 16792844]
2. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Müllerian inhibiting substance in humans: normal levels from infancy to adulthood. *J Clin Endocrinol Metab*. 1996; 81:571–6. [PubMed: 8636269]
3. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. *J Clin Endocrinol Metab*. 2006; 91:4057–63. [PubMed: 16804046]
4. van Rooij IA, Broekmans FJ, Hunault CC, Scheffer GJ, Eijkemans MJ, de Jong FH, et al. Use of ovarian reserve tests for the prediction of ongoing pregnancy in couples with unexplained or mild male infertility. *Reprod Biomed Online*. 2006; 12:182–90. [PubMed: 16478583]
5. Dorgan JF, Stanczyk FZ, Eggleston BL, Kahle LL, Shaw CM, Spittle CS, et al. Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk. *J Natl Cancer Inst*. 2009; 101:1501–9. [PubMed: 19820206]
6. Harrell, FE. Regression modeling strategies with applications to linear models. New York: Springer-Verlag; 2001.
7. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimüllerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. *Fertil Steril*. 2005; 83:979–87. [PubMed: 15820810]
8. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimüllerian hormone serum levels: a putative marker for ovarian aging. *Fertil Steril*. 2002; 77:357–62. [PubMed: 11821097]
9. van Rooij IA, Tonkelaar I, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, et al. Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition. *Menopause*. 2004; 11:601–6. [PubMed: 15545787]
10. Arbo E, Vettori DV, Jimenez MF, Freitas FM, Lemos N, Cunha-Filho JS. Serum anti-müllerian hormone levels and follicular cohort characteristics after pituitary suppression in the late luteal phase with oral contraceptive pills. *Hum Reprod*. 2007; 22:3192–6. [PubMed: 17981819]
11. van den Berg MH, van Dulmen-den Broeder E, Overbeek A, Twisk JW, Schats R, van Leeuwen FE, et al. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. *Hum Reprod*. 2010; 25:1520–7. [PubMed: 20348556]

12. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. *Fertil Steril*. 2008; 90:395–400. [PubMed: 17919608]
13. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. *Eur J Obstet Gynecol Reprod Biol*. 2007; 134:196–201. [PubMed: 17335955]
14. Goldzieher JW, Stanczyk FZ. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. *Contraception*. 2008; 78:4–9. [PubMed: 18555811]
15. Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF 3rd. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. *Fertil Steril*. 2007; 87:101–6. [PubMed: 17109858]
16. Su HI, Sammel MD, Freeman EW, Lin H, DeBlasis T, Gracia CR. Body size affects measures of ovarian reserve in late reproductive age women. *Menopause*. 2008; 15:857–61. [PubMed: 18427357]
17. Steiner AZ, Stanczyk FZ, Patel S, Edelman A. Antimullerian hormone and obesity: insights in oral contraceptive users. *Contraception*. 2010; 81:245–8. [PubMed: 20159182]
18. Nardo LG, Christodoulou D, Gould D, Roberts SA, Fitzgerald CT, Laing I. Anti-Mullerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. *Gynecol Endocrinol*. 2007; 23:486–93. [PubMed: 17852428]
19. Plante BJ, Cooper GS, Baird DD, Steiner AZ. The impact of smoking on antimullerian hormone levels in women aged 38 to 50 years. *Menopause*. 2010; 17:571–6. [PubMed: 20065884]
20. Cook CL, Siow Y, Taylor S, Fallat ME. Serum mullerian-inhibiting substance levels during normal menstrual cycles. *Fertil Steril*. 2000; 73:859–61. [PubMed: 10731554]
21. La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, et al. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. *Hum Reprod*. 2004; 19:2738–41. [PubMed: 15459174]
22. La Marca A, Stabile G, Arsenio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. *Hum Reprod*. 2006; 21:3103–7. [PubMed: 16923748]
23. van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC, et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. *Hum Reprod*. 2010; 25:221–7. [PubMed: 19840990]
24. Al-Qahtani A, Groome NP. Editorial: Anti-Mullerian hormone: Cinderella finds new admirers. *J Clin Endocrinol Metab*. 2006; 91:3760–2. [PubMed: 17028290]
25. Liberty G, Ben-Chetrit A, Margalioth EJ, Hyman JH, Galoyan N, Eldar-Geva T. Does estrogen directly modulate anti-mullerian hormone secretion in women? *Fertil Steril*. 2010; 94:2253–6. [PubMed: 20356582]
26. Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. *Fertil Steril*. 2002; 77:141–6. [PubMed: 11779604]
27. Piltonen T, Koivunen R, Morin-Papunen L, Ruokonen A, Huhtaniemi IT, Tapanainen JS. Ovarian and adrenal steroid production: regulatory role of LH/HCG. *Hum Reprod*. 2002; 17:620–4. [PubMed: 11870113]
28. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. *J Clin Endocrinol Metab*. 2003; 88:5957–62. [PubMed: 14671196]
29. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. *Hum Reprod*. 2005; 20:1820–6. [PubMed: 15802325]
30. Dorgan J, Spittle CS, Eggleston BL, Shaw CM, Kahle LL, Brinton LA. Assay reproducibility and within-person variation of mullerian inhibiting substance. *Fertil Steril*. 2010; 94:301–4. [PubMed: 19409547]

Table 1

Selected subgroup relationships to AMH concentration

Characteristic	n	Age-adjusted median AMH level (pmol/L)	95% CI	P value	Age and OCP-adjusted median AMH level (pmol/L)	95% CI	P value
Age (y)							
33.3–39.8	33	7.85	5.21–9.90	<.0001 ^a	n/a	n/a	n/a
39.8–41.6	34	4.28	2.86–6.57		n/a	n/a	n/a
41.6–43.0	34	3.57	2.14–5.85		n/a	n/a	n/a
43.1–44.9	34	0.50	0.21–1.43		n/a	n/a	n/a
Height (cm)							
≤160	37	4.43	3.21–5.71	.84 ^a	4.50	3.64–5.43	.68 ^a
>160, ≤164	29	4.21	3.14–5.40		4.43	3.78–5.07	
>164, ≤168	35	4.36	3.14–2.48		4.28	3.57–5.07	
>168	34	4.28	2.21–6.35		4.21	3.07–5.28	
BMI (kg/m ²)							
<25	82	4.36	3.50–5.21	.76 ^a	4.50	3.71–4.57	.66 ^a
≥25, <30	32	4.14	1.21–7.07		4.43	3.71–5.07	
≥30	21	4.57	3.43–5.64		4.28	3.36–5.21	
Age at menarche (y)							
9–11	22	4.78	3.00–6.57	.17 ^a	4.86	3.71–5.93	.29 ^a
12–14	100	4.28	3.43–5.07		4.28	3.71–4.86	
15–17	13	3.14	1.50–4.71		3.71	2.50–5.00	
Menstrual cycle phase							
Follicular	32	4.36	3.07–5.64	.66	4.57	3.57–5.50	.73
Periovulatory	23	4.78	1.93–7.71		4.43	3.64–5.21	
Luteal	54	4.78	3.57–6.07		4.36	3.64–5.07	
Unknown	26	4.14	3.14–5.07		4.14	3.28–5.07	
Age at first term pregnancy (y)							
<20	30	3.64	2.43–4.86	.47 ^a	4.21	3.28–5.07	.51 ^a
≥20, <25	72	4.64	3.72–5.57		4.50	3.78–5.21	
≥25, <30	25	5.07	2.14–8.07		4.71	3.43–6.07	
≥30	3	4.14	0.14–8.21		5.00	2.93–7.07	

Characteristic	n	Age-adjusted median AMH level (pmol/L)	95% CI	P value	Age and OCP-adjusted median AMH level (pmol/L)	95% CI	P value
Number of full term pregnancies							
0	5	3.07	-0.36-6.50	.22 ^a	4.57	0.93-8.21	.70 ^a
1-2	56	4.78	3.57-6.00		4.64	3.57-5.71	
3-4	59	4.14	3.28-4.93		4.43	3.78-5.07	
>4	15	3.28	1.29-5.28		4.14	2.86-5.50	
Oral contraceptives							
Hormone users	14	3.00	2.07-3.86	.001	n/a	n/a	n/a
Hormone nonusers	121	4.57	3.86-5.21		n/a	n/a	
Smoking							
Never	81	4.50	3.57-5.36	.39	4.36	3.57-5.14	.57
Previous smokers	24	3.64	2.43-4.78		4.43	3.78-5.07	
Current smokers	30	4.57	3.43-5.64		4.50	3.57-5.36	
Hour of collection							
8-9 AM	23	3.86	2.50-5.21	.46	4.43	2.93-5.93	.44
10-11 AM	39	3.78	2.86-4.71		3.64	2.78-4.50	
12-1 PM	41	4.64	3.28-6.00		4.64	3.28-5.93	
2-3 PM	32	4.71	3.64-5.78		4.57	3.36-5.78	
Season of collection							
Winter	33	4.57	2.57-6.50	.73	4.43	3.36-5.50	.97
Spring	47	3.93	3.07-4.78		4.36	3.64-5.14	
Summer	29	4.78	3.21-6.35		4.28	3.57-5.07	
Fall	26	4.07	2.71-5.43		4.28	3.14-5.36	

^aTrend *P* value, additional *P* values across categories are *P* for heterogeneity.

Shaw. Correspondence. Fertil Steril 2011.